Skip to main content

Table 4 Comparison of RV functions in the control group vs. thrombolysis group

From: Clinical outcomes of submassive pulmonary embolism thrombolysis—an Indian experience

  Control group Thrombolysis group
N (%) p value N (%) p value
Dilated RA/RV Pre vs. post 20 (45.5%) vs. 20 (45.5%) (n = 44) 1.000 26 (61.9%) vs. 11 (26.2%) (n = 42) 0.001*
Pre vs. day 30 14 (40.0%) vs. 13 (37.1%) (n = 35) 1.000 21 (58.3%) vs. 6 (16.7%) (n = 36) 0.001*
Post vs. day 30 14 (40.0%) vs. 13 (37.1%) (n = 35) 1.000 10 (27.8%) vs. 6 (16.7%) (n = 36) 0.344
RV systolic dysfunction Pre vs. post 24 (54.5%) vs. 21 (47.7%) (n = 44) 0.629 22 (52.4%) vs. 8 (19.0%) (n = 42) 0.004*
Pre vs. day 30 19 (37.1%) vs. 11 (31.4%) (n = 35) 0.096 19 (52.8%) vs. 3 (8.3%) (n = 36) 0.0001*
Post vs. day 30 19 (54.3%) vs. 11 (31.4%) (n = 35) 0.057 5 (13.9%) vs. 3 (8.3%) (n = 36) 0.727
Tricuspid regurgitation Pre Mild 5 (11.4%) 0.064 7 (16.7%) 0.0001*
Moderate 29 (65.9%) 22 (52.4%)
Sever 10 (22.7%) 13 (31.0%)
Post Mild 15 (34.1%) 32 (76.2%)
Moderate 22 (50.0%) 10 (23.8%)
Sever 7 (15.9%) 0 (0.0%)
Pre Mild 4 (11.4%) 0.011* 6 (16.7%) 0.0001*
Moderate 22 (62.9%) 20 (55.6%)
Sever 9 (25.7%) 10 (27.8%)
Day 30 Mild 15 (42.9%) 23 (63.9%)
Moderate 15 (42.9%) 13 (36.1%)
Sever 5 (14.3%) 0 (0.0%)
Post Mild 12 (34.3%) 0.678 26 (72.2%) 0.678
Moderate 18 (51.4%) 10 (27.8%)
Sever 5 (14.3%) 0 (0.0%)
Day 30 Mild 15 (42.9%) 23 (63.9%)
Moderate 15 (42.9%) 13 (36.1%)
Sever 5 (14.3%) 0 (0.0%)
  1. *p value < 0.05, statistically significant
  2. Pre pre-treatment, post post-treatment (within 48 h of treatment)